The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity
We examined the expression levels of the multidrug resistance protein 5 ( ABCC5 ) gene in non–small cell lung cancer (NSCLC) cell lines to clarify the relationship with the sensitivity to gemcitabine. The expression levels of ABCC5 were inversely correlated with gemcitabine sensitivity significantly...
Saved in:
Published in | Molecular cancer therapeutics Vol. 5; no. 7; pp. 1800 - 1806 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Association for Cancer Research
01.07.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We examined the expression levels of the multidrug resistance protein 5 ( ABCC5 ) gene in non–small cell lung cancer (NSCLC) cell lines to clarify the relationship with the sensitivity to gemcitabine. The
expression levels of ABCC5 were inversely correlated with gemcitabine sensitivity significantly ( r = 0.628; P < 0.01) in 17 NSCLC cells, whereas the expression of ABCC5 in the gemcitabine-resistant NSCLC cell line H23/GEM-R was the same as that in parental NCI-H23 cells. Treatment with the
ABCC5 inhibitor zaprinast altered the sensitivity to gemcitabine in ABCC5-expressing NSCLC cells. In addition, decreasing
the expression of ABCC5 by small interfering RNA altered the cytotoxicity to gemcitabine. These results indicate that modulation of ABCC5 activity
could be used to increase the gemcitabine sensitivity in NSCLC. Previously, we found a decreased expression of deoxycytidine
kinase in H23/GEM-R cells, and further investigation in this study showed an increased expression of ribonucleotide reductase
subunit 1 in H23/GEM-R cells. We therefore also examined the effect of modifying the expression of both genes on gemcitabine
resistance. We found that using small interfering RNA to decrease the expression of ribonucleotide reductase subunit 1 resulted in a decreased resistance to gemcitabine in H23/GEM-R cells. Furthermore, pretreatment with pemetrexed resulted
in an increased deoxycytidine kinase expression concomitant with the alteration of the resistance to gemcitabine in H23/GEM-R cells. The determinants for sensitivity
and the acquired resistance in gemcitabine are quite different; nonetheless, modification of these factors may increase the
efficacy of gemcitabine in the treatment of NSCLC. [Mol Cancer Ther 2006;5(7):1800–6] |
---|---|
AbstractList | We examined the expression levels of the multidrug resistance protein 5 (ABCC5) gene in non-small cell lung cancer (NSCLC) cell lines to clarify the relationship with the sensitivity to gemcitabine. The expression levels of ABCC5 were inversely correlated with gemcitabine sensitivity significantly (r = 0.628; P < 0.01) in 17 NSCLC cells, whereas the expression of ABCC5 in the gemcitabine-resistant NSCLC cell line H23/GEM-R was the same as that in parental NCI-H23 cells. Treatment with the ABCC5 inhibitor zaprinast altered the sensitivity to gemcitabine in ABCC5-expressing NSCLC cells. In addition, decreasing the expression of ABCC5 by small interfering RNA altered the cytotoxicity to gemcitabine. These results indicate that modulation of ABCC5 activity could be used to increase the gemcitabine sensitivity in NSCLC. Previously, we found a decreased expression of deoxycytidine kinase in H23/GEM-R cells, and further investigation in this study showed an increased expression of ribonucleotide reductase subunit 1 in H23/GEM-R cells. We therefore also examined the effect of modifying the expression of both genes on gemcitabine resistance. We found that using small interfering RNA to decrease the expression of ribonucleotide reductase subunit 1 resulted in a decreased resistance to gemcitabine in H23/GEM-R cells. Furthermore, pretreatment with pemetrexed resulted in an increased deoxycytidine kinase expression concomitant with the alteration of the resistance to gemcitabine in H23/GEM-R cells. The determinants for sensitivity and the acquired resistance in gemcitabine are quite different; nonetheless, modification of these factors may increase the efficacy of gemcitabine in the treatment of NSCLC. Abstract We examined the expression levels of the multidrug resistance protein 5 (ABCC5) gene in non–small cell lung cancer (NSCLC) cell lines to clarify the relationship with the sensitivity to gemcitabine. The expression levels of ABCC5 were inversely correlated with gemcitabine sensitivity significantly (r = 0.628; P < 0.01) in 17 NSCLC cells, whereas the expression of ABCC5 in the gemcitabine-resistant NSCLC cell line H23/GEM-R was the same as that in parental NCI-H23 cells. Treatment with the ABCC5 inhibitor zaprinast altered the sensitivity to gemcitabine in ABCC5-expressing NSCLC cells. In addition, decreasing the expression of ABCC5 by small interfering RNA altered the cytotoxicity to gemcitabine. These results indicate that modulation of ABCC5 activity could be used to increase the gemcitabine sensitivity in NSCLC. Previously, we found a decreased expression of deoxycytidine kinase in H23/GEM-R cells, and further investigation in this study showed an increased expression of ribonucleotide reductase subunit 1 in H23/GEM-R cells. We therefore also examined the effect of modifying the expression of both genes on gemcitabine resistance. We found that using small interfering RNA to decrease the expression of ribonucleotide reductase subunit 1 resulted in a decreased resistance to gemcitabine in H23/GEM-R cells. Furthermore, pretreatment with pemetrexed resulted in an increased deoxycytidine kinase expression concomitant with the alteration of the resistance to gemcitabine in H23/GEM-R cells. The determinants for sensitivity and the acquired resistance in gemcitabine are quite different; nonetheless, modification of these factors may increase the efficacy of gemcitabine in the treatment of NSCLC. [Mol Cancer Ther 2006;5(7):1800–6] We examined the expression levels of the multidrug resistance protein 5 ( ABCC5 ) gene in non–small cell lung cancer (NSCLC) cell lines to clarify the relationship with the sensitivity to gemcitabine. The expression levels of ABCC5 were inversely correlated with gemcitabine sensitivity significantly ( r = 0.628; P < 0.01) in 17 NSCLC cells, whereas the expression of ABCC5 in the gemcitabine-resistant NSCLC cell line H23/GEM-R was the same as that in parental NCI-H23 cells. Treatment with the ABCC5 inhibitor zaprinast altered the sensitivity to gemcitabine in ABCC5-expressing NSCLC cells. In addition, decreasing the expression of ABCC5 by small interfering RNA altered the cytotoxicity to gemcitabine. These results indicate that modulation of ABCC5 activity could be used to increase the gemcitabine sensitivity in NSCLC. Previously, we found a decreased expression of deoxycytidine kinase in H23/GEM-R cells, and further investigation in this study showed an increased expression of ribonucleotide reductase subunit 1 in H23/GEM-R cells. We therefore also examined the effect of modifying the expression of both genes on gemcitabine resistance. We found that using small interfering RNA to decrease the expression of ribonucleotide reductase subunit 1 resulted in a decreased resistance to gemcitabine in H23/GEM-R cells. Furthermore, pretreatment with pemetrexed resulted in an increased deoxycytidine kinase expression concomitant with the alteration of the resistance to gemcitabine in H23/GEM-R cells. The determinants for sensitivity and the acquired resistance in gemcitabine are quite different; nonetheless, modification of these factors may increase the efficacy of gemcitabine in the treatment of NSCLC. [Mol Cancer Ther 2006;5(7):1800–6] |
Author | Yuko Takano Mikinori Miyazaki Hideki Muramatsu Hiroyuki Achiwa Hiroyoshi Maeda Tetsuya Oguri Shigeki Sato Takashi Niimi Yuji Bessho Ryuzo Ueda |
Author_xml | – sequence: 1 givenname: Tetsuya surname: Oguri fullname: Oguri, Tetsuya email: t-oguri@med.nagoya-cu.ac.jp organization: Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. t-oguri@med.nagoya-cu.ac.jp – sequence: 2 givenname: Hiroyuki surname: Achiwa fullname: Achiwa, Hiroyuki – sequence: 3 givenname: Shigeki surname: Sato fullname: Sato, Shigeki – sequence: 4 givenname: Yuji surname: Bessho fullname: Bessho, Yuji – sequence: 5 givenname: Yuko surname: Takano fullname: Takano, Yuko – sequence: 6 givenname: Mikinori surname: Miyazaki fullname: Miyazaki, Mikinori – sequence: 7 givenname: Hideki surname: Muramatsu fullname: Muramatsu, Hideki – sequence: 8 givenname: Hiroyoshi surname: Maeda fullname: Maeda, Hiroyoshi – sequence: 9 givenname: Takashi surname: Niimi fullname: Niimi, Takashi – sequence: 10 givenname: Ryuzo surname: Ueda fullname: Ueda, Ryuzo |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16891466$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkE9PwyAYh4nRODf9CBpunqowCmu9zcZ_icbLPBMKbzdMSyd0Gm9-B09-PT-J1Jq4CxDye34vPGO061oHCB1TckYpz84pZzyZUcHOHopFQkRCyJTvoIN4nyUZp-nu73nIjNA4hGdCaJZP6T4aUZHlNBXiAH0tVoANdOAb65TrAm4rHMAF29lX271j5QxW-mVjPRjsIdjQKacBdy1eQqNtp0rrYoWtKvDYOhzf-f3xGRpV11hDXOqNW2LdQ_4CK-zbGvoh88ui4D2wXbM1-RDtVaoOcPS3T9DT9dWiuE3uH2_uivl9olPCu2Q2YykjqiwZpcYQRoRWhKVC5TmfQjqNv9SVEaWqcjAlZDDLGUk5L1OowKicTRAferVvQ_BQybW3jfLvkhLZq5a9RtlrlFG1JEL2qiN3MnDrTdmA-af-3MbA6RBY2eXqLfqTg4QoEZTXKxlLJc0IYT80443o |
CitedBy_id | crossref_primary_10_1186_s12864_022_08591_9 crossref_primary_10_1158_1535_7163_MCT_07_2088 crossref_primary_10_1080_14728222_2017_1310841 crossref_primary_10_1038_s41420_022_00951_4 crossref_primary_10_1111_j_1349_7006_2009_01358_x crossref_primary_10_1002_cncr_25510 crossref_primary_10_1593_neo_10576 crossref_primary_10_1016_j_bbrc_2015_02_044 crossref_primary_10_4161_cbt_20843 crossref_primary_10_3892_ijo_2013_2229 crossref_primary_10_1208_s12248_020_00467_8 crossref_primary_10_18632_oncotarget_13544 crossref_primary_10_1124_dmd_110_033613 crossref_primary_10_3892_ol_2012_773 crossref_primary_10_1016_j_critrevonc_2009_11_006 crossref_primary_10_1016_j_jphs_2015_01_006 crossref_primary_10_1371_journal_pone_0223554 crossref_primary_10_2217_pgs_14_159 crossref_primary_10_1097_FPC_0000000000000086 crossref_primary_10_1080_07391102_2020_1742793 crossref_primary_10_1016_j_biopha_2021_111730 crossref_primary_10_1266_ggs_22_00093 crossref_primary_10_1016_S1470_2045_10_70244_8 crossref_primary_10_1038_tpj_2016_17 crossref_primary_10_1016_j_lungcan_2009_07_013 crossref_primary_10_1016_j_acthis_2014_09_002 crossref_primary_10_3390_biomedicines11051384 crossref_primary_10_1016_j_cellsig_2014_07_001 crossref_primary_10_1158_1535_7163_MCT_06_0529 crossref_primary_10_1016_j_lungcan_2007_06_005 crossref_primary_10_1016_j_biomaterials_2013_07_050 crossref_primary_10_1182_blood_2008_03_143040 crossref_primary_10_1038_tpj_2009_53 crossref_primary_10_3390_cells9010029 crossref_primary_10_1517_17530059_2013_826645 crossref_primary_10_1016_j_molonc_2013_04_004 crossref_primary_10_1016_j_canlet_2016_11_035 crossref_primary_10_2217_pgs_10_70 crossref_primary_10_1007_s12274_022_4525_x crossref_primary_10_1016_j_bcp_2011_12_042 crossref_primary_10_1186_s12885_018_4332_7 crossref_primary_10_1021_mp200261n crossref_primary_10_1371_journal_pone_0092320 crossref_primary_10_1016_j_jconrel_2015_01_026 crossref_primary_10_1016_j_redox_2019_101131 crossref_primary_10_3109_10428191003713968 crossref_primary_10_1007_s00280_010_1515_6 crossref_primary_10_1016_j_canlet_2007_06_012 crossref_primary_10_1186_s12864_016_3322_x crossref_primary_10_3390_cancers3010106 crossref_primary_10_1038_mt_2013_120 crossref_primary_10_1007_s11095_021_03072_2 crossref_primary_10_3892_or_2023_8666 crossref_primary_10_3390_ph7020169 crossref_primary_10_3892_ol_2017_6591 crossref_primary_10_1111_j_1440_1827_2011_02772_x crossref_primary_10_1016_j_lungcan_2011_08_003 crossref_primary_10_1016_j_tvjl_2015_04_025 crossref_primary_10_1002_cbf_4079 crossref_primary_10_1158_0008_5472_CAN_08_2819 crossref_primary_10_18632_oncotarget_19458 crossref_primary_10_1016_j_lfs_2022_121171 crossref_primary_10_1111_jgh_15289 |
Cites_doi | 10.1016/S0006-2952(02)01484-3 10.1158/1535-7163.MCT-04-0291 10.1074/jbc.M005463200 10.1124/mol.104.009373 10.1158/1078-0432.CCR-03-0156 10.1158/0008-5472.CAN-03-3363 10.1002/(SICI)1097-0215(20000401)86:1<95::AID-IJC15>3.0.CO;2-G 10.1002/ijc.1369 10.1158/1078-0432.CCR-03-0520 10.1073/pnas.120159197 10.1056/NEJMoa011954 10.2174/1389200043489199 10.1200/JCO.2005.13.953 10.1016/S1368-7646(02)00002-X 10.1016/S1470-2045(02)00788-X 10.1111/j.1349-7006.2004.tb03257.x 10.1124/mol.63.5.1094 10.1038/sj.onc.1206952 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1158/1535-7163.MCT-06-0025 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-8514 |
EndPage | 1806 |
ExternalDocumentID | 10_1158_1535_7163_MCT_06_0025 16891466 5_7_1800 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 08R 123 2WC 34G 39C 3O- 53G 55 5RE 5VS AAPBV ABFLS ABOCM ACIWK ACPRK ADACO ADBBV ADBIT AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBS EJD F5P GX1 H13 H~9 IH2 KQ8 L7B MVM O0- OK1 P2P RCR RHF RHI WOQ X7M ZA5 ZXP --- .55 18M 2FS AAJMC ACGFO ADCOW AFHIN BR6 BTFSW CGR CUY CVF ECM EIF NPM QTD TR2 W8F WHG YBU ZGI AAYXX CITATION |
ID | FETCH-LOGICAL-c405t-773430abb311dd0306ca0346a9952e42466cfd6baf9edbe8e7930455b4efeda93 |
ISSN | 1535-7163 |
IngestDate | Fri Aug 23 03:44:26 EDT 2024 Sat Sep 28 08:34:50 EDT 2024 Fri Jan 15 19:23:15 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c405t-773430abb311dd0306ca0346a9952e42466cfd6baf9edbe8e7930455b4efeda93 |
PMID | 16891466 |
PageCount | 7 |
ParticipantIDs | crossref_primary_10_1158_1535_7163_MCT_06_0025 pubmed_primary_16891466 highwire_cancerresearch_5_7_1800 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 2000 |
PublicationDate | 20060701 2006-Jul 2006-07-01 |
PublicationDateYYYYMMDD | 2006-07-01 |
PublicationDate_xml | – month: 07 year: 2006 text: 20060701 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular cancer therapeutics |
PublicationTitleAlternate | Mol Cancer Ther |
PublicationYear | 2006 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | 2022060808080734100_BIB19 2022060808080734100_BIB18 2022060808080734100_BIB13 2022060808080734100_BIB12 2022060808080734100_BIB11 2022060808080734100_BIB10 2022060808080734100_BIB17 2022060808080734100_BIB16 2022060808080734100_BIB15 2022060808080734100_BIB14 2022060808080734100_BIB9 2022060808080734100_BIB6 2022060808080734100_BIB5 2022060808080734100_BIB8 2022060808080734100_BIB7 2022060808080734100_BIB2 2022060808080734100_BIB20 2022060808080734100_BIB1 2022060808080734100_BIB4 2022060808080734100_BIB3 2022060808080734100_BIB24 2022060808080734100_BIB23 2022060808080734100_BIB22 2022060808080734100_BIB21 2022060808080734100_BIB25 |
References_xml | – ident: 2022060808080734100_BIB24 doi: 10.1016/S0006-2952(02)01484-3 – ident: 2022060808080734100_BIB20 doi: 10.1158/1535-7163.MCT-04-0291 – ident: 2022060808080734100_BIB16 doi: 10.1074/jbc.M005463200 – ident: 2022060808080734100_BIB18 doi: 10.1124/mol.104.009373 – ident: 2022060808080734100_BIB3 – ident: 2022060808080734100_BIB5 – ident: 2022060808080734100_BIB25 – ident: 2022060808080734100_BIB8 – ident: 2022060808080734100_BIB22 doi: 10.1158/1078-0432.CCR-03-0156 – ident: 2022060808080734100_BIB9 doi: 10.1158/0008-5472.CAN-03-3363 – ident: 2022060808080734100_BIB14 doi: 10.1002/(SICI)1097-0215(20000401)86:1<95::AID-IJC15>3.0.CO;2-G – ident: 2022060808080734100_BIB15 doi: 10.1002/ijc.1369 – ident: 2022060808080734100_BIB17 doi: 10.1158/1078-0432.CCR-03-0520 – ident: 2022060808080734100_BIB12 – ident: 2022060808080734100_BIB11 doi: 10.1073/pnas.120159197 – ident: 2022060808080734100_BIB13 doi: 10.1056/NEJMoa011954 – ident: 2022060808080734100_BIB10 doi: 10.2174/1389200043489199 – ident: 2022060808080734100_BIB2 – ident: 2022060808080734100_BIB23 doi: 10.1200/JCO.2005.13.953 – ident: 2022060808080734100_BIB4 doi: 10.1016/S1368-7646(02)00002-X – ident: 2022060808080734100_BIB1 doi: 10.1016/S1470-2045(02)00788-X – ident: 2022060808080734100_BIB7 – ident: 2022060808080734100_BIB6 doi: 10.1111/j.1349-7006.2004.tb03257.x – ident: 2022060808080734100_BIB19 doi: 10.1124/mol.63.5.1094 – ident: 2022060808080734100_BIB21 doi: 10.1038/sj.onc.1206952 |
SSID | ssj0018921 |
Score | 2.191595 |
Snippet | We examined the expression levels of the multidrug resistance protein 5 ( ABCC5 ) gene in non–small cell lung cancer (NSCLC) cell lines to clarify the... We examined the expression levels of the multidrug resistance protein 5 (ABCC5) gene in non-small cell lung cancer (NSCLC) cell lines to clarify the... Abstract We examined the expression levels of the multidrug resistance protein 5 (ABCC5) gene in non–small cell lung cancer (NSCLC) cell lines to clarify the... |
SourceID | crossref pubmed highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1800 |
SubjectTerms | ABCC5 Antimetabolites, Antineoplastic - pharmacology Antimetabolites, Antineoplastic - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Cell Line, Tumor Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use deoxycytidine kinase Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics gemcitabine Gene Expression Glutamates - pharmacology Guanine - analogs & derivatives Guanine - pharmacology Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Multidrug Resistance-Associated Proteins - antagonists & inhibitors Multidrug Resistance-Associated Proteins - genetics Multidrug Resistance-Associated Proteins - metabolism non–small cell lung cancer Pemetrexed Phosphodiesterase Inhibitors - pharmacology Purinones - pharmacology ribonucleotide reductase RNA, Small Interfering - genetics RNA, Small Interfering - pharmacology Tumor Suppressor Proteins - antagonists & inhibitors Tumor Suppressor Proteins - genetics |
Title | The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity |
URI | http://mct.aacrjournals.org/content/5/7/1800.abstract https://www.ncbi.nlm.nih.gov/pubmed/16891466 |
Volume | 5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELbKIiEuaPkvC8gHblVKm9j54dYtoAIqHOhKyymyE6cN0HbVJkK7L7KvwGMyYzupqYoEXKIqjsdJ5qvnG2dmTMiLUAoGtD0E5qakx3ypPLDjwpOcSbA-SSFCTE6efgwnZ-z9OT_vdH46UUt1JfvZ1cG8kv_RKpwDvWKW7D9othUKJ-A36BeOoGE4_rWO8714li1GpNstIXQh1gxjfRUmqWyRK-IfGfjmXC2zshISSabZJAVXPlbrlbdd4tdqXNDvfa8xIxe7bExSdBOLODodjzl2cMU4I7uUd9pswGsl9ZyUr5bQf5rXJuV9pqptfdnailG2KH9ofjspN-vL-lvZLgkJvQFU7_OinKvd6VOYuRe64Uv9tdxf04iaNY1mGuYeeHKBO09zB46RM-cOY13r9IAx4Jjg0MrqL7NKB3kNTKq1A5CLpUbIMIwTsBx7pbmNr2SbbpCbfpRwDB59_e5D-70qTnxbmdeMZXPF4A5eHhwfa9Vaib8ToqZI9Z6Xo9nO7JjcsW4KHRnM3SUdtbpHbk1tIMZ9cg3Qoy706LqgDgAoQI820KM76NFqTR3MUAM9Wq5oCz2K0KMIPWoA84oKisDDITTw8HJXiDPuA3L29s1sPPHsHh9eBq5CBVNEwIKBkDIYDvMcHdhMDAIWiiThvmI-vKCsyGFGKRKVSxUrsCfghXDJVKFykQQPyRHcoHpMKNCsQgIhLaI4ZuAGCO4nWSSCGPrGUZF3Sb950emFKeWSaheYxykqKUUlpdPxLNWhnj7vEtqoIzUPbAtwLVK4OEXcdckjo6adRKvWJ39sOSG3d5h_So6qTa2eAbOt5HMNql_1q6TK |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+determinants+of+sensitivity+and+acquired+resistance+to+gemcitabine+differ+in+non-small+cell+lung+cancer%3A+a+role+of+ABCC5+in+gemcitabine+sensitivity&rft.jtitle=Molecular+cancer+therapeutics&rft.au=Oguri%2C+Tetsuya&rft.au=Achiwa%2C+Hiroyuki&rft.au=Sato%2C+Shigeki&rft.au=Bessho%2C+Yuji&rft.date=2006-07-01&rft.issn=1535-7163&rft.volume=5&rft.issue=7&rft.spage=1800&rft_id=info:doi/10.1158%2F1535-7163.mct-06-0025&rft_id=info%3Apmid%2F16891466&rft.externalDocID=16891466 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-7163&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-7163&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-7163&client=summon |